Heteroaryl-substituted naphthalenes and structurally modified derivatives: Selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis

Journal of Medicinal Chemistry

Volumn 48, Issue 21, 2005, Pages 6632-6642

  Voets, Marieke ^a   Antes, Iris ^b   Scherer, Christiane ^a   Müller Vieira, Ursula ^a   Biemel, Klaus ^c   Barassin, Catherine ^c   Marchais Oberwinkler, Sandrine ^a   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^c Pharmacelsus CRO   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 DICHLORO 6 METHOXY 2 NAPHTHALEN 2 OL; 1,5 DICHLORO 6 METHOXY 2 NAPHTHYLTRIFLUOROMETHANESULFONATE; 3 (6 METHOXY 2 NAPHTHYL)PYRIDINE; 6 CYANO 2 NAPHTHYLTRIFLUOROMETHANESULFONATE; ALDOSTERONE SYNTHASE; ANDROSTENEDIONE; AROMATASE; CORTICOSTEROID; CYTOCHROME P450 11B1; CYTOCHROME P450 17; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DEOXYCORTICOSTERONE; DRUG METABOLITE; KETOCONAZOLE; NAPHTHALENE DERIVATIVE; PROGESTERONE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; COMPETITIVE INHIBITION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; HAMSTER; HEART MUSCLE FIBROSIS; HUMAN; IN VITRO STUDY; LIVER MICROSOME; LUNG FIBROBLAST; MALE; MOLECULAR DYNAMICS; NONHUMAN; RAT; SCHIZOSACCHAROMYCES POMBE; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION;

ALDOSTERONE SYNTHASE; AROMATASE; AROMATASE INHIBITORS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; FIBROSIS; HEART FAILURE, CONGESTIVE; HUMANS; LIVER; MICROSOMES, LIVER; MODELS, MOLECULAR; MYOCARDIUM; NAPHTHALENES; SCHIZOSACCHAROMYCES; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27144472491     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0503704     Document Type: Article

References (54)

1. Kawamoto, T.; Mitsuuchi, Y.; Toda, K.; Yokoyama, Y.; Miyakara, K.; Miura, S.; Onishi, T.; Ichihawa, Y.; Nakao, K.; Imura, H.; Ulick, S.; Shizuta, Y. Role of steroid 11β-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 1458-1462.
2. Brilla, C. G. Aldosterone and myocardial fibrosis in heart failure. Herz 2000, 25, 299-306.
3. Lijnen, P.; Petrov, V. Induction of cardiac fibrosis by aldosterone. J. Mol. Cell. Cardiol. 2000, 32, 865-879.
4. Pitt, B.; Zannad, F.; Remme, W. J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Eng. J. Med. 1999, 341, 709-717.
5. Pitt, B.; Remme, W. J.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Eng. J. Med. 2003, 348, 1309-21.
6. Khan, N. U. A.; Movahed, A. The role of aldosterone and aldosterone-receptor antagonists in heart failure. Rev. Cardiovasc. Med. 2004, 5, 71-81.
7. Juurlink, D. N.; Mamdani, M. M.; Lee, D. S.; Kopp, A.; Austin, P. C.; Laupacis, A.; Redelmeier, D. A. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N. Engl. J. Med. 2004, 351, 543-551.
8. Hartmann, R. W. Selective inhibition of steroidogenic P450 enzymes: current status and future perspectives. Eur. J. Pharm. Sci. 1994, 2, 15-16.
9. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Müller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): Screening in fission yeast and evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179.
10. Hartmann, R. W.; Müller, U.; Ehmer, P. B. Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. Eur. J. Med. Chem. 2003, 38, 363-366.
11. (a) Hartmann, R. W.; Bayer, H.; Grün, G.; Sergejew, T.; Bartz, U.; Mitrenga, M. Pyridyl-substituted tetrahydrocyclopropa[α]naphthalenes: Highly active and selective inhibitors of P450 arom. J. Med. Chem. 1995, 38, 2103-2111.
12. 2 synthase and aromatase. J. Med. Chem. 2000, 43, 1841-1851.
13. (c) Recanatini, M.; Bisi, A.; Cavalli, A.; Belluti, F.; Gobbi, S.; Rampa, A.; Valenti, P.; Palzer, M.; Palusczak, A.; Hartmann, R. W. A new class of nonsteroidal aromatase inhibitors: Design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17α-hydroxylase/C17,20-lyase. J. Med. Chem. 2001, 44, 672-680.
14. (d) Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Palusczak, A.; Hartmann, R. W.; Carotti, A. Design, synthesis and 3D QSAR of novel potent and selective aromatase inhibitors. J. Med. Chem. 2004, 47, 6792-6803.
15. (a) Wachall, B. G.; Hector, M.; Zhuang, Y.; Hartmann, R. W. Imidazole substituted biphenyls: A new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer. Bioorg. Med. Chem. 1999, 7, 1913-1924.
16. (b) Hartmann, R. W.; Hector, M.; Wachall, B. G.; Palusczak, A.; Palzer, M.; Huch, V.; Veith, M. Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17α-hydroxylase/C17-20- lyase (P450 17). J. Med. Chem. 2000, 43, 4437-4445.
17. (c) Zhuang, Y.; Wachall, B. G.; Hartmann, R. W. Novel imidazolyl and triazolyl substituted biphenyl compounds: Synthesis and evaluation as nonsteroidal inhibitors of human 17α-hydroxylase-C17,20-lyase (P450 17). Bioorg. Med. Chem. 2000, 8, 1245-1252.
18. (d) Haidar, S.; Ehmer, P. B.; Barassin, S.; Batzl-Hartmann, C.; Hartmann, R. W. Effects of novel 17α-hydroxylase/C17,20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J. Steroid Biochem. Mol. Biol. 2003, 84, 555-562.
19. Taymans, S. E.; Pack, S.; Pak, E.; Torpy, D. J.; Zhuang, Z.; Stratakis, C. A. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J. Clin. Endocrinol. Metab. 1998, 83, 1033-1036.
20. Häusler, A.; Monnet, G.; Borer, C.; Bhatnagar, A. S. Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal. J. Steroid Biochem. 1989, 34, 567-570.
21. Demers, L. M.; Melby, J. C.; Wilson, T. E.; Lipton, A.; Harvey, H. A.; Santen, R. J. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. J. Clin. Endocrinol. Metab. 1990, 70, 1162-1166.
22. Bureik, M.; Hubel, K.; Dragan, C. A.; Scher, J.; Becker, H.; Lenz, N.; Bernhardt, R. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Mol. Cell. Endocrinol. 2004, 217, 249-254.
23. Ulmschneider, S.; Müller-Vieira, U.; Mitrenga, M.; Hartmann, R. W.; Oberwinkler-Marchais, S.; Klein, C. D.; Bureik, M.; Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation of imidazolylmethylene- tetrahydronaphthalenes and imidazolylmethylene-indanes: Potent inhibitors of aldosterone synthase. J. Med. Chem. 2005, 48, 1796-1805.
24. Ulmschneider, S.; Müller-Vieira, U.; Klein, C. D.; Antes, I.; Lengauer, T.; Hartmann, R. W. Synthesis and evaluation of (pyridylmethylene) tetrahydronaphthalenes/-indanes and structurally modified derivatives: Potent and selective inhibitors of aldosterone synthase. J. Med. Chem. 2005, 48, 1563-1575.
25. Miyaura, N.; Suzuki, N. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
26. Huisgen, R.; Sorge, G. Orientating phenomena in the substitution on aromatic bicyclic compounds. III. Radical substitutions in the naphthalene group. Liebigs Ann. Chem. 1950, 566, 162-184.
27. Ono, S.; Inoue, Y.; Yoshida, T.; Ashimori, A.; Kosaka, K.; Imada, T.; Fukaya, C.; Nakamura, N. Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 1. The selection of naphthalene derivatives. Chem. Pharm. Bull. 1999, 49, 1685-1693.
28. Mewshaw, R. E.; Edsall, R. J.; Yang, C.; Harris, H. A.; Keith, J. C.; Albert, L. M. (Wyeth). Substituted phenyl naphthalenes as estrogenic agents. Patent WO03051805, 2003.
29. Young, T. E.; Amstutz, E. D. Halogen reactivities. Certain heterocyclic iminohalide systems. J. Am. Chem. Soc. 1951, 4773-4775.
30. Jagdmann, G. E.; Munson, H. R.; Gero, T. W. A mild efficient procedure for the conversion of carboxylic acid esters to primary amides using formamide/methanolic sodium methoxide. Synth. Commun. 1990, 20, 1203-1208.
31. Lam, P. Y. S.; Clark, C. G.; Saubern, S.; Adams, J.; Winters, M. P.; Chan, D. M. T.; Combs, A. New aryl/heteroaryl C-N bond cross-coupling reactions via arylboronic acid/cupric acetate arylation. Tetrahedron Lett. 1998, 39, 2941-2944.
32. Lan, J.; Chen, L.; Yu, X.; You, J.; Xie, R. A simple copper salt catalysed the coupling of imidazole with arylboronic acids in protic solvent. Chem. Commun. 2004, 2, 188-189.
33. Bredereck, H.; Theilig, G. Imidazolsynthesen mit Formamid. Chem. Ber. 1953, 86, 88-96.
34. Denner, K.; Doehmer, J.; Bernhardt, R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 chinese hamster cells. Endocr. Res. 1995, 21, 443-448.
35. Thompson, E. A.; Siiteri, P. K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J. Biol. Chem. 1974, 249, 5364-5372.
36. Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl) piperidine-2,6-diones. J. Med. Chem. 1986, 29, 1362-1369.
37. 17,20-lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli. J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63.
38. Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent nonsteroidal CYP17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant enzyme. J. Enzyme Inhib. Med. Chem. 2004, 19, 17-32.
39. Hidalgo, I. J. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 2001, 1, 385-401.
40. Yee, S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in men - fact or myth. Pharm. Res. 1997, 14, 763-766.
41. Tannergren, C.; Langguth, P.; Hoffmann, K. J. Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity. Pharmazie 2001, 56, 337-342.
42. Laitinen, L.; Kangas, H.; Kaukonen, A. M.; Hakala, K.; Kotiaho, R.; Kostiainen, R.; Hirvonen, J. N-in-one permeability studies of heterogeneous sets of compounds across Caco-2 cell monolayers. Pharm. Res. 2003, 20, 187-197.
43. Saito, H.; Fukasawa, Y.; Otsubo, Y.; Yamada, K.; Sezaki, H.; Yamashita, S. Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers. Pharm. Res. 2000, 17, 761-765.
44. Belkina, N. V.; Lisurek, M.; Ivanov, A. S.; Bernhardt, R. Modelling of three-dimensional structures of cytochromes P450 11B2 and 11B1. J. Inorg. Biochem. 2001, 87, 197-207.
45. Chowdhury, S.; Georghiou, P. E. Palladium catalyzed cross-coupling between phenyl- or naphthylboronic acids and benzylic bromides. Tetrahedron Lett. 1999, 40, 7599-7603.
46. Li, W.; Nelson, D. P.; Jensen, M. S.; Hoerrner, R. S.; Cai, D.; Larsen, R. D.; Reider, P. J. An improved protocol for the preparation of 3-pyridyl- and some arylboronic acids. J. Org. Chem. 2002, 67, 5394-5397.
47. Kauffmann, T.; Tigler, D.; Woltermann, A. Kondensation von 3-(1-Imidazolyl)- und -(1-Benzimidazolyl)-chinolin zu Heterocyclotetraaromaten. Chem. Ber. 1982, 115, 452-458.
48. Kajigaeshi, S.; Kakinami, T.; Okamoto, T.; Fujisaki, S. Synthesis of bromoacetyl derivatives by use of tetrabutylammonium tribromide. Bull. Chem. Soc. Jpn. 1987, 60, 1159-1160.
49. Dahn, H.; Zoller, P. Über die katalytische Hydrogenolyse von Derivaten des p-Phenylbenzylamins. Helv. Chim. Acta 1952, 35, 1348-1351.
50. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome P4502C9 with bound warfarin. Nature 2003, 424, 464-468.
51. Hindle, S. A.; Rarey, M.; Buning, C.; Lengauer, T. Flexible docking under pharmacophore type constraints. J. Comput. Aided Mol. Des. 2002, 16, 129-149.
52. Scott, W. R. P.; Hünenberger, P. H.; Tironi, I. G.; Mark, A. E.; Billeter, S. R.; Fennen, J.; Torda, A. E.; Huber, T.; Krüger, P.; van Gunsteren, W. F. The GROMOS Biomolecular Simulation Program Package. J. Phys. Chem. A 1999, 103, 3596-3607.
53. Lindahl, E.; Hess, B.; van der Spoel, D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J. Mol. Mod. 2001, 7, 306-317.
54. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; Hermans, J. Interaction models for water in relation to protein hydration. In Intermolecular Forces; Pullman, B., Ed.; Reidel Publishing Co.: Dordrecht, 1981; pp 331-342.